Cell Source

Cell Source Change in Working Capital

The Change in Working Capital of Cell Source (CLCS) as of Oct 19, 2026 is 1.16 M USD. In the previous year, Change in Working Capital was 1.76 M USD — a change of -33.84% (lower).

Change in Working Capital

1.16 MUSD

YoY

-33.84%

Last updated:

Change in Working Capital of Cell Source is 2025 1.16 M USD. Change in Working Capital of Cell Source was 2024 1.76 M USD. It decreases by -33.84% lower compared to the previous year.

The Cell Source Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
292,141.00 USD
Jan 1, 2019
570,087.00 USD
Jan 1, 2020
423,338.00 USD
Jan 1, 2021
701,240.00 USD
Jan 1, 2022
1.56 M USD
Jan 1, 2023
2.22 M USD
Jan 1, 2024
1.76 M USD
Jan 1, 2025
1.16 M USD
The Cell Source Change in Working Capital history
YEARChange in Working CapitalYoY
1.16 MUSD-33.84%
1.76 MUSD-20.63%
2.22 MUSD+41.89%
1.56 MUSD+122.97%
701,240.00USD+65.65%
423,338.00USD-25.74%
570,087.00USD+95.14%
292,141.00USD+111.95%
137,833.00USD-85.57%
955,352.00USD+336.77%
218,733.00USD-2,360.34%
-9,677.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cell Source Stock analysis

What does Cell Source do? Cell Source Inc., based in New York City, operates in the Health Care sector as a biotechnology company specializing in immunotherapy. The company, listed on 14 January 2014, focuses on developing Veto Cell technology, an immune tolerance biotechnology enabling selective immune response blocking. Its lead product targets allogeneic hematopoietic stem cell transplantation, supporting haploidentical transplants with mild conditioning. The pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and non-malignant disorders. The firm holds a wholly owned subsidiary, Cell Source Limited. Cell Source is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Source stock

Change in Working Capital of Cell Source is 1.16 M USD in 2025.

Change in Working Capital of Cell Source changed from 1.76 M USD to 1.16 M USD, representing a -33.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Cell Source since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Cell Source historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Cell Source

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Cell Source